CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Current and Future PET Imaging for Multiple Myeloma.
Current and Future PET Imaging for Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
正电子发射断层成像（PET）是一种无创评估肿瘤分期和治疗应答的影像方式。¹⁸F标记氟代脱氧葡萄糖PET（¹⁸F-FDG PET）广泛用于评估多发性骨髓瘤（MM）患者的活动性和非活动性病灶。尽管¹⁸F-FDG PET已用于MM管理，但其敏感性低于新一代流式细胞术和测序技术。因此，研究者开发了新型PET放射性示踪剂⁶⁴Cu-LLP2A、⁶⁸Ga-pentixafor和⁸⁹Zr-daratumumab，以靶向MM细胞表面抗原。此外，近期研究尝试在癌症患者中使用PET成像显示TIL（肿瘤浸润淋巴细胞），并探讨其预后作用，但尚未在MM患者中开展。本文总结¹⁸F-FDG及新型放射性示踪剂用于检测MM的近期研究、MM小鼠模型临床前研究及临床研究。未来，新型PET技术或可用于开发MM治疗策略。
Positron emission tomography (PET) is an imaging modality used for the noninvasive assessment of tumor staging and response to therapy. PET with 18 F labeled fluorodeoxyglucose ( 18 F-FDG PET) is widely used to assess the active and inactive lesions in patients with multiple myeloma (MM). Despite the availability of 18 F-FDG PET for the management of MM, PET imaging is less sensitive than next-generation flow cytometry and sequencing.
Therefore, the novel PET radiotracers 64 Cu-LLP2A, 68 Ga-pentixafor, and 89 Zr-daratumumab have been developed to target the cell surface antigens of MM cells.
Furthermore, recent studies attempted to visualize the tumor-infiltrating lymphocytes using PET imaging in patients with cancer to investigate their prognostic effect; however, these studies have not yet been performed in MM patients. This review summarizes the recent studies on PET with 18 F-FDG and novel radiotracers for the detection of MM and the resulting preclinical research using MM mouse models and clinical studies. Novel PET technologies may be useful for developing therapeutic strategies for MM in the future.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
